Insider sells 20,000 CORT shares after option exercise (CORT)
Rhea-AI Filing Summary
Corcept Therapeutics (CORT) notice under Rule 144 reports a sale of 20,000 common shares tied to a stock option exercise on 04/07/2026 for $817,000 via Stifel Nicolaus & Company. The filing lists prior sales by William Guyer in 02/03/2026 (20,000 shares, $817,333), 03/04/2026 (8,233 shares, $296,346), and 03/20/2026 (11,767 shares, $423,707).
Positive
- None.
Negative
- None.
Insights
Rule 144 sale notice records option exercise followed by resale reporting.
The filing documents a stock option exercise and subsequent sale of 20,000 common shares on 04/07/2026, with proceeds shown as $817,000. It also itemizes three prior sales by the same registrant in early 2026.
These entries serve as a transfer/resale disclosure under Rule 144; cash‑flow recipient is the seller as disclosed via the broker entry. Timing and broader ownership context are not provided in the excerpt.